COVID-19, an Incentive to Tackle Sugar in Hospitals and at Home

Obesity and metabolic disease are thwarting our efforts to recover from COVID-19. Chronic inflammation is a key feature of both COVID-19 and the metabolic syndrome. Sugar consumption in particular has been shown to affect COVID-19 mortality by contributing to the chronic inflammatory state. Restriction of free sugar intake has a measurable effect on disease-predicting physiological parameters in as little as 9 days. The rapid reduction in inflammation following fructose restriction is key in the context of the COVID-19 pandemic, as COVID-19 exacerbates the same inflammatory pathways as those driven by the metabolic syndrome. Healthcare providers have a duty to implement international recommendations of reduced free sugar intake. By doing so, they could reduce the chronic inflammatory burden contributing to COVID-19 patients’ demise. Further, it would set a precedent for reducing the risk of severe disease in the uninfected, by maximizing their potential metabolic health in the context of an infection predicated on its disruption.